{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:52:10Z","timestamp":1788447130461,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd001537.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000}}],"reference-count":66,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001537.pub5","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T16:39:40Z","timestamp":1646152780000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Interventions for minimal change disease in adults with nephrotic syndrome"],"prefix":"10.1002","volume":"2022","author":[{"given":"Karolis","family":"Azukaitis","sequence":"additional","affiliation":[{"name":"Clinic of Pediatrics, Institute of Clinical Medicine, Faculty of Medicine; Vilnius University; Vilnius Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Otago Christchurch; Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M","family":"Hodson","sequence":"additional","affiliation":[{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"issue":"5720","key":"10.1002\/14651858.CD001537.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/bmj.3.5720.421","article-title":"Controlled trial of prednisone in adult patients with the nephrotic syndrome","volume":"3","author":"Black","year":"1970","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0002|cit2","first-page":"18","article-title":"Adult minimal change nephropathy: experience of the collaborative study of glomerular disease","volume":"97","author":"Coggins","year":"1986","journal-title":"Transactions of the American Clinical & Climatological Asoociation"},{"issue":"1","key":"10.1002\/14651858.CD001537.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ndt\/gfp422","article-title":"Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome","volume":"25","author":"Eguchi","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6505","key":"10.1002\/14651858.CD001537.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/bmj.291.6505.1305","article-title":"Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome","volume":"291","author":"Imbasciati","year":"1985","journal-title":"British Medical Journal Clinical Research Ed"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD001537.pub5-BIB0005|cit5","first-page":"402A","article-title":"The combination of very low-dose prednisolone with cyclosporine as an initial treatment for minimal change nephrotic syndrome (MCNS) in adults [abstract no: F-PO1272]","volume":"21","author":"Inoue","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD001537.pub5-BIB0006|cit6","first-page":"240","article-title":"A controlled trial of levamisole in frequently relapsing minimal change disease [abstract]","volume":"26","author":"Kirubakaran","year":"1984","journal-title":"Kidney International"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD001537.pub5-BIB0007|cit7","first-page":"240A","article-title":"Tacrolimus monotherapy follows intravenous methyprednisolone in adults with minimal change nephrotic syndrome: a prospective, multi-centered, open, randomized, controlled trial [abstract no: TH-PO662]","volume":"26","author":"Li","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD001537.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1681\/ASN.2016030342","article-title":"Tacrolimus monotherapy after intravenous methylprednisolone in adults with minimal change nephrotic syndrome","volume":"28","author":"Li","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD001537.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/qjmed\/hcz297","article-title":"Low-dose corticosteroid and mycophenolate for primary treatment of minimal change disease","volume":"113","author":"Ma","year":"2020","journal-title":"QJM"},{"issue":"2","key":"10.1002\/14651858.CD001537.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial.[Erratum in: Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1027; PMID: 32518101]","volume":"15","author":"Medjeral-Thomas","year":"2020","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"5","key":"10.1002\/14651858.CD001537.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1440-1797.2006.00667.x","article-title":"Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation","volume":"11","author":"Miao","year":"2006","journal-title":"Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD001537.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.kint.2018.07.021","article-title":"An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study)","volume":"94","author":"Remy","year":"2018","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD001537.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/1319-2442.252902","article-title":"Tacrolimus as the first-line agent in adult-onset minimal change disease: A randomized controlled study","volume":"30","author":"Patil","year":"2019","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD001537.pub5-BIB0014|cit14","first-page":"327A","article-title":"Combined cyclosporine and prednisolone therapy in adults with new-onset minimal change nephrotic syndrome [abstract no: TH-PO1003]","volume":"24","author":"Shirai","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD001537.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10157-017-1443-4","article-title":"Combined cyclosporine and prednisolone therapy using cyclosporine blood concentration monitoring for adult patients with new-onset minimal change nephrotic syndrome: a single-center pilot randomized trial","volume":"22","author":"Shirai","year":"2018","journal-title":"Clinical & Experimental Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD001537.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1681\/ASN.2019050546","article-title":"Comparison of the efficacy and safety of tacrolimus and low-dose corticosteroid with high-dose corticosteroid for minimal change nephrotic syndrome in adults","volume":"32","author":"Chin","year":"2021","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0017|cit17","unstructured":"Redacted clinical study report synopsis DSN: PRGNS-11-02-KOR astellasclinicalstudyresults.com\/docs\/PRGNS-11-02-KOR\/Redacted%20Synopsis\/prgns-11-02-kor-clrrs-02-disc01-en-final-02.pdf"},{"issue":"4","key":"10.1002\/14651858.CD001537.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1445-5994.1983.tb04479.x","article-title":"Intravenous methylprednisolone pulse therapy in minimal change nephrotic syndrome","volume":"13","author":"Yeung","year":"1983","journal-title":"Australian & New Zealand Journal of Medicine"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000415387","article-title":"Unconjugated hyperbilirubinemia due to ciclosporin administration in children with nephrotic syndrome","volume":"67","author":"Edefonti","year":"1988","journal-title":"Contributions to Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD001537.pub5-BIB0020|cit20","first-page":"C8","article-title":"Unconjugated hyperbilirubinemia due to cyclosporin a (CyA) administration in children with nephrotic syndrome (NS) [abstract no: F1.12]","volume":"1","author":"Edefonti","year":"1987","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0021|cit21","unstructured":"Edefonti A Ghio L Rizzoni G Rinaldi S Gusmano R Lama G Cyclosporine (CSA) vs cyclophosphamide (CYC) for children with frequently relapsing\/steroid dependant nephrotic syndrome (FR\/SDNS): long term study [abstract] 9th Congress. International Pediatric Nephrology Association; 1992 Aug 30 - Sep 4; Jerusalem, Israel 1992 C70"},{"issue":"3","key":"10.1002\/14651858.CD001537.pub5-BIB0022|cit22","first-page":"310","article-title":"Cyclosporine (CSA) vs cyclophosphamide (CYC) for children with frequently relapsing\/steroid dependent nephrotic syndrome (FR\/SDNS): long term study [abstract]","volume":"3","author":"Edefonti","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD001537.pub5-BIB0023|cit23","first-page":"1326","article-title":"Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial","volume":"8","author":"Ponticelli","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000168206","article-title":"Ciclosporin in minimal-change glomerulopathy and in focal segmental glomerular sclerosis","volume":"10 Suppl 1","author":"Ponticelli","year":"1990","journal-title":"American Journal of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD001537.pub5-BIB0025|cit25","first-page":"147","article-title":"A multicenter controlled prospective trial with cyclosporine vs cyclophosphamide in frequent relapsers and steroid dependent patients with idiopathic nephrotic syndrome","volume":"2","author":"Ponticelli","year":"1989","journal-title":"Journal of Nephrology"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0026|cit26","unstructured":"Ponticelli C Ciclosporin in the treatment of idiopathic nephrotic syndrome [abstract] 10th Asian Colloquium in Nephrology; 1994 Dec 2-6; Karachi, Pakistan 1994 116"},{"issue":"5","key":"10.1002\/14651858.CD001537.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.1993.tb12723.x","article-title":"Renal effects of cyclosporin A in children treated for idiopathic nephrotic syndrome","volume":"82","author":"Tirelli","year":"1993","journal-title":"Acta Paediatrica"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD001537.pub5-BIB0028|cit28","first-page":"305A","article-title":"Mycophenolate mofetil combined with low dose of prednisolone in treating adults with minimal change nephrotic syndrome and concomitant HBsAg positive [abstract no: TH-PO865]","volume":"19","author":"Li","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD001537.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/ki.1993.194","article-title":"A randomized trial of cyclosporine in steroid resistant idiopathic nephrotic syndrome","volume":"43","author":"Ponticelli","year":"1993","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD001537.pub5-BIB0030|cit30","first-page":"201","article-title":"One-year, alternate day dosage, corticosteroid Rx reduces rate of further relapses in adult minimal change nephrosis [abstract]","volume":"35","author":"Simon","year":"1989","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD001537.pub5-BIB0031|cit31","first-page":"442","article-title":"A randomised controlled unblinded multicentre non-inferiority trial with activated vitamin D and prednisolone treatment in patients with minimal change nephropathy (ADAPTinMCN)","volume":"22","author":"Kristensen","year":"2021","journal-title":"Trials [Electronic Resource]"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001537.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"i405","DOI":"10.1093\/ndt\/gfy104.SP180","article-title":"A randomized controlled, Danish multicenter trial in minimal change nephropathy: The efficacy of high dose prednisolone vs. reduced prednisolone dose and activated vitamin D [abstract no: SP180]","volume":"33","author":"Kristensen","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0033|cit33","unstructured":"Ramachandran R Steroid tapering protocol in adult nephrotic syndrome due to MCD- a randomised control trial of 2 regimens - MCD www.ctri.nic.in\/Clinicaltrials\/pmaindet2 php?trialid=13216"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0034|cit34","unstructured":"Deegens HK Wetzels JF Efficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome www.ClinicalTrials.gov\/show\/NCT03298698"},{"issue":"1","key":"10.1002\/14651858.CD001537.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ekir.2017.08.013","article-title":"Randomized clinical trial design to assess abatacept in resistant nephrotic syndrome","volume":"3","author":"Trachtman","year":"2018","journal-title":"Kidney International Reports"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001537.pub5-BIB0036|cit36","first-page":"56","article-title":"Analysis of duration of remission as an intention-to-treat analysis with application to the TURING trial [abstract no: P-194]","volume":"20","author":"Qian","year":"2019","journal-title":"Trials [Electronic Resource]"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0037|cit37","unstructured":"Willcocks L Griffith M TURING - the use of rituximab in the treatment of nephrotic glomerulonephritis - clinical trial protocol V2.0 njl-admin.nihr.ac.uk\/document\/download\/2030929"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fped.2015.00078","article-title":"The evidence-based approach to adult-onset idiopathic nephrotic syndrome","volume":"3","author":"Canetta","year":"2015","journal-title":"Frontiers in Pediatrics"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1523-1755.2004.00831.x","article-title":"The Italian experience of the national registry of renal biopsies","volume":"66","author":"Gesualdo","year":"2004","journal-title":"Kidney International"},{"issue":"7650","key":"10.1002\/14651858.CD001537.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD001537.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD001537.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ndt\/18.2.245","article-title":"Recent approaches to the pathogenesis of minimal-change nephrotic syndrome","volume":"18","author":"Grimbert","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD001537.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/0272-6386(95)90437-9","article-title":"Increasing incidence of focal-segmental glomerulosclerosis among adult nephropathies: a 20-year renal biopsy study","volume":"26","author":"Haas","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD001537.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0272-6386(97)90485-6","article-title":"Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997","volume":"30","author":"Haas","year":"1997","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1002\/14651858.CD001537.pub5-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001533.pub6","article-title":"Corticosteroid therapy for nephrotic syndrome in children","author":"Hahn","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7414","key":"10.1002\/14651858.CD001537.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0047|cit47","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"5","key":"10.1002\/14651858.CD001537.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"702-11","DOI":"10.1681\/ASN.2012070734","article-title":"The treatment of minimal change disease in adults","volume":"24","author":"Hogan","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4S","key":"10.1002\/14651858.CD001537.pub5-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1016\/j.kint.2021.05.021","article-title":"Chapter 5: Minimal change disease (MCD) in adults","volume":"100","year":"2021","journal-title":"Kidney International Supplements"},{"issue":"5","key":"10.1002\/14651858.CD001537.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0272-6386(96)90098-0","article-title":"The racial prevalence of glomerular lesions in nephrotic adults","volume":"27","author":"Korbet","year":"1996","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD001537.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"911-3","DOI":"10.2215\/CJN.01920219","article-title":"Management of adult minimal change disease","volume":"14","author":"Korbet","year":"2019","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"4","key":"10.1002\/14651858.CD001537.pub5-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002290.pub5","article-title":"Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children","author":"Larkins","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD001537.pub5-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003594.pub6","article-title":"Interventions for idiopathic steroid-resistant nephrotic syndrome in children","author":"Liu","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD001537.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/jcm8060860","article-title":"Levamisole in children with idiopathic nephrotic syndrome: clinical efficacy and pathophysiological aspects","volume":"8","author":"M\u00fchlig","year":"2019","journal-title":"Journal of Clinical Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001537.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD001537.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/ajkd.2002.31400","article-title":"Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome","volume":"39","author":"Nakayama","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD001537.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/ki.1986.130","article-title":"Adult-onset minimal change nephrotic syndrome: a long-term follow-up","volume":"29","author":"Nolasco","year":"1986","journal-title":"Kidney International"},{"issue":"8","key":"10.1002\/14651858.CD001537.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.drudis.2016.06.009","article-title":"Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?","volume":"21","author":"Reddy","year":"2016","journal-title":"Drug Discovery Today"},{"issue":"3","key":"10.1002\/14651858.CD001537.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00467-018-3929-z","article-title":"Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome","volume":"34","author":"Schijvens","year":"2019","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0060|cit60","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD001537.pub5-BIB0061|cit61","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD001537.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ndt\/gfg134","article-title":"Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses","volume":"18","author":"Tse","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD001537.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"332-45","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD001537.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics,treatment, and outcomes","volume":"2","author":"Waldman","year":"2007","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"7","key":"10.1002\/14651858.CD001537.pub5-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001537.pub3","article-title":"Interventions for minimal change disease in adults with nephrotic syndrome","author":"Palmer","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD001537.pub5-BIB0066|cit66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001537.pub4","article-title":"Interventions for minimal change disease in adults with nephrotic syndrome","author":"Palmer","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T06:51:24Z","timestamp":1667976684000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001537.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":66,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001537.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}